RT Journal Article
T1 Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics
A1 Portolés Pérez, Antonio
A1 Rivas Paterna, Ana Belén
A1 Sánchez Pernaute, Andrés
A1 Torres García, Antonio José
A1 Moreno Lopera, Carmen
A1 Chicharro, Luis M.
A1 Bandrés Moya, Fernando
A1 López Picado, Amanda
A1 Rubio, Miguel A.
A1 Vargas Castrillón, Emilio
AB Introduction: The prevalence of obesity is increasing globally. The principal aim was to evaluate whether gastric bypass surgery modifies the bioavailability and pharmacokinetic (PK) parameters of omeprazole. Methods: Controlled, open-label, bioavailability clinical trial in patients undergoing Roux-en-Y gastric bypass (RYGB). Healthy patients with obesity (body mass index >35) were included and assessed for omeprazole PKs before and after RYGB (1 and 6 months). PK sampling was done at baseline and several times up to 12 h after drug dosing. Pre- and post-surgery parameters were compared using paired ANOVA or Wilcoxon tests, and control versus cases using ANOVA or Mann-Whitney tests. Given the post-surgery change in body weight, parameters were corrected by dose/body weight. Results: Fourteen case and 24 control subjects were recruited; 92% were women (N = 35/38). In patients who underwent RYGB, maximum plasma concentration (Cmax) was significantly reduced at 1 and 6 months after surgery compared with presurgery values (p = 0.001). Regarding the AUC, the values are lower at 1 and 6 months after surgery than at baseline (p < 0.001). The drug clearance was also increased in the first month after surgery. No differences were found between patients 6 months after surgery and controls. Cmax and AUC corrected by dose/body weight were significantly different between the baseline surgery subjects and controls. Discusion/Conclusions: Omeprazole bioavailability is reduced in patients with obesity at 1 and 6 months after RYGB. However, omeprazole PK parameters 6 months after RYGB are similar to control subjects, and thus no dose correction is required after RYGB for a given indication.
PB S. Karger AG
SN 1662-4025
YR 2022
FD 2022-01-03
LK https://hdl.handle.net/20.500.14352/123509
UL https://hdl.handle.net/20.500.14352/123509
LA eng
NO Portolés-Pérez A, Paterna ABR, Sánchez Pernaute A, García AJT, Lopera CM, Chicharro LM, et al. Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics. Obesity Facts. 2022;15(2):271-80.
NO Este estudio ha sido financiado por la Fundación Mutua Madrileña, VIII convocatoria de Ayudas a la Investigación en Salud, 2011.
DS Docta Complutense
RD 28 dic 2025